Analyses from clinical trials in urothelial carcinoma have indicated that APOBEC mutational signatures and high TMB are both associated with improved outcomes with immunotherapy agents including both anti-PD-1 antibody nivolumab and anti-PD-L1 antibody atezolizumab (9, 11, 16, 25). Here, CD274 is linked to urothelial carcinoma.